Deutsche Bank Repeats Buy Rating for Teva

Haaretz Staff
Send in e-mailSend in e-mail
Haaretz Staff

Deutsche Bank yesterday issued a Buy rating for Teva Pharmaceuticals. Subsequent to Teva's "rare profit warning," analysts David Steinberg, Rhett Brown and Edward Chung took the Israeli drug company's advice and lowered their earnings per share forecasts for the company by four cents, aftre the U.S. court ruling stopping Teva's launch of its generic version of Abbott's Biaxin.

They confess to being surprised that "a potential launch at risk was `baked into' Teva's guidance" whereas it should have been left outside, as a potential upside. But the court ruling showcases the challenging nature of the current environment, they wrote, and Teva is also hurting from a relative paucity of new launches this year.



Automatic approval of subscriber comments.

NOW: 40% OFF
Already signed up? LOG IN


הקלטות מעוז

Jewish Law Above All: Recordings Reveal Far-right MK's Plan to Turn Israel Into Theocracy

איתמר בן גביר

Why I’m Turning My Back on My Jewish Identity

Travelers looking at the Departures board at Ben Gurion Airport. The number of olim who later become yordim is unknown.

Down and Out: Why These New Immigrants Ended Up Leaving Israel

Beatrice Grannò and Simona Tabasco as Mia and Lucia in "The White Lotus."

The Reality Behind ‘The White Lotus’ Sex Work Fantasy

The Mossad hit team in Dubai. Exposed by dozens of security cameras

This ‘Dystopian’ Cyber Firm Could Have Saved Mossad Assassins From Exposure

מליאת הכנסת 28.12.22

Comeback Kid: How Netanyahu Took Back Power After 18 Months in Exile